Las Vegas – September 21, 2026 -- Concept Medical's MagicTouch sirolimus-coated balloon will face fresh scrutiny at VIVA 2026 as researchers unveil new subgroup data from the SirPAD randomized trial covering 597 patients treated for femoropopliteal peripheral artery disease without tissue loss.
SirPAD enrolled 1,252 patients to compare drug-coated and uncoated balloon angioplasty
The academic, investigator-initiated trial randomized 1,252 patients with symptomatic infrainguinal peripheral artery disease to angioplasty using either the MagicTouch PTA sirolimus-coated balloon or an uncoated balloon. Primary results, published in the New England Journal of Medicine, showed the sirolimus-coated balloon arm was both non-inferior and superior to the uncoated balloon on major adverse limb events (MALE) at one year.
New analysis targets patients seeking symptom relief rather than limb salvage
The upcoming late-breaking presentation narrows the focus to 597 trial participants with femoropopliteal disease and intermittent claudication but no tissue loss. For this population, revascularization goals shift from limb preservation toward durable relief of walking-related symptoms, making the subgroup data commercially relevant for device makers targeting claudicant patients rather than critical limb ischemia cases alone.
Presentation scheduled for VIVA 2026's late-breaking clinical trial program
Prof. Dr. Stefano Barco, co-principal investigator of SirPAD, will present the findings at VIVA 2026, running October 3-6 at Bellagio Las Vegas. The meeting is among the leading international forums dedicated to peripheral vascular disease and endovascular therapy, drawing device manufacturers and interventionalists evaluating next-generation drug-delivery technologies for coronary and peripheral procedures.